Clearmind Medicine (CMND) announced the filing of a new international patent application for a proprietary treatment targeting anorexia, bulimia and other eating disorders. The patent application covers the use of 3-Methylmethcathinone in combination with Palmitoylethanolamide. This combination aims to address the complex neurobiological and psychological factors associated with eating disorders, offering a potential new avenue for treatment.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Psychedelic: Clearmind completes clinical site initiations for AUD trial
- Clearmind Medicine completes initiation of AUD Phase I/IIa trial
- Psychedelic: MindMed announces dosing in Phase 3 Emerge study
- Clearmind Medicine receives notice of allowance for U.S. patent
- Clearmind Medicine launches first U.S. clinical site for AUD trial
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue